Please tell us about your clinical experience. How many patients with Radiation-Induced Xerostomia do you see on a yearly basis? What is the standard of care and what treatments are available?

How often do patients who have had radiotherapy of the oral cavity and neck region complain of xerostomia?

How much of a need is there for novel treatments ? Where do you see AAV-hAQP1 fitting in this space? What other upcoming therapies are you excited about?

How often does xerostomia lead to complications, like tooth decay and mouth sores?

How often is pilocarpine (Salagen) or cevimeline (Evoxac) prescribed to stimulate saliva production? How well do these medications work?

How often does radiation-induced apoptosis develop into radiation-induced necrosis of the salivary glands?

What percent of your patients have residual salivary function? What difference in effectiveness of AAV-hAQP1 do you think this can make?

Can you please discuss the company’s Xerostomia Questionnaire PRO measure results:-6 of 7 participants reaching the Day 90 assessment reported decreases in disease burden of 10 points or more on the XQ – indicating a clinically meaningful alleviation in disease burden; a change in disease burden score of 6 is considered clinically meaningful-More dramatic reductions of 19, 25, 26, and 41 points were reported by 4 of 7 participants at Day 90-In the participants who completed visits at Day 180 and 360, scores continued to improve or were stable at these later timepoints-One participant reported complete resolution of symptoms at Day 360 following treatment with no symptoms of xerostomia (a score of 0 for all symptom scores), and has maintained the same score of 0 following the 24 month assessment

Could you please also tell us your opinion on the McMaster Global Rate of Change PRO measure results:-6 of the 7 participants who reached the Day 90 assessment reported their symptoms of dry mouth as better following treatment-All 6 of these participants rated changes in xerostomia scores that were important or very important to the participant (a score of 2 or more)-3 participants rated the change in xerostomia symptoms with the highest level of improvement (scores of 6 or 7)-Improvement in xerostomia symptoms persisted through 1 year in two of the patients who reached Day 360-Participant 1-1 has just reached the 24-month assessment and the highest possible score of 7 was maintained-Participant 2-1 reported no improvement and was the only one of the 7 participants who had no saliva production at baseline-No participant reported a worsening of xerostomia symptoms at any time point